| Literature DB >> 26598514 |
Christophe Le Tourneau1, Maud Kamal1, Apostolia-Maria Tsimberidou1, Philippe Bedard1, Gaëlle Pierron1, Céline Callens1, Etienne Rouleau1, Anne Vincent-Salomon1, Nicolas Servant1, Marie Alt1, Roman Rouzier1, Xavier Paoletti1, Olivier Delattre1, Ivan Bièche1.
Abstract
With the advent of high-throughput molecular technologies, several precision medicine (PM) studies are currently ongoing that include molecular screening programs and PM clinical trials. Molecular profiling programs establish the molecular profile of patients' tumors with the aim to guide therapy based on identified molecular alterations. The aim of prospective PM clinical trials is to assess the clinical utility of tumor molecular profiling and to determine whether treatment selection based on molecular alterations produces superior outcomes compared with unselected treatment. These trials use treatment algorithms to assign patients to specific targeted therapies based on tumor molecular alterations. These algorithms should be governed by fixed rules to ensure standardization and reproducibility. Here, we summarize key molecular, biological, and technical criteria that, in our view, should be addressed when establishing treatment algorithms based on tumor molecular profiling for PM trials.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26598514 PMCID: PMC4830395 DOI: 10.1093/jnci/djv362
Source DB: PubMed Journal: J Natl Cancer Inst ISSN: 0027-8874 Impact factor: 13.506